Compare Immunovant Inc. Common Stock (IMVT) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Consumer Staples Select Sector SPDR Fund — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while Consumer Staples Select Sector SPDR Fund trades at $83.05 (market cap $13.44B). The key difference: Consumer Staples Select Sector SPDR Fund is far larger — about 2× Immunovant Inc. Common Stock's market cap, and Consumer Staples Select Sector SPDR Fund is more actively traded (9,437,177 versus 1,131,364). Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| IMVT | XLP | |
|---|---|---|
Market Cap | $6.62B | $13.44B |
Volume | 1,131,364 | 9,437,177 |
Sector | Health | — |
52-Week High | $44.96 | $90.00 |
52-Week Low | $17.03 | $75.61 |
Typical Hold Time | 0 Days | 72 Days |
Enterprise Value | $5.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XLP trades at $81.70, down 0.09% with a bearish technical outlook as moving averages signal selling pressure. The ETF shows strong analyst support with a 100% buy rating from 2 analysts. Recent news highlights XLP's 6.6% YTD gain outperforming discretionary peers, though it faces headwinds from rising interest rates pressuring dividend stocks.
XLP offers defensive exposure to consumer staples with a low 0.08% expense ratio and upcoming dividend. Key risks include persistent inflation and interest rate sensitivity, but the fund's quality holdings provide stability during market volatility. The technical setup suggests near-term consolidation around current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
